Exchange: NASDAQ
Industry: Pharmaceuticals & Biotechnology
Last Trade: 4:00 PM ET 4/5/2013
Last 10 Quotes:
What's This?
| Fiscal Q4 Ending 12/12 |
Fiscal Q3 Ending 09/12 |
Fiscal Q2 Ending 06/12 |
Fiscal Q1 Ending 03/12 |
Fiscal Q4 Ending 12/11 |
|
Sales/Revenue |
0 | 0 | 0 | 0 | 0 |
Cost of Goods Sold (COGS) incl. D&A |
70 | 54 | 40 | 32 | 0 |
COGS excluding D&A |
0 | 0 | 0 | 0 | 0 |
Depreciation & Amortization Expense |
70 | 54 | 40 | 32 | NA |
Gross Income |
-71 | -55 | -41 | -33 | 0 |
SG&A Expense |
21,543 | 14,630 | 13,156 | 9,713 | 12,707 |
Research & Development |
8,558 | 6,521 | 5,449 | 4,634 | 8,150 |
Other SG&A |
12,984 | 8,108 | 7,707 | 5,078 | 4,556 |
Other Operating Expense |
0 | 0 | 0 | 0 | 0 |
Unusual Expense |
-12 | 0 | 546 | 830 | 911 |
Non Operating Income/Expense |
-40 | -29 | -13 | -802 | 43 |
Equity in Affiliates (Pretax) |
NA | 0 | 0 | 0 | 0 |
Interest Expense |
204 | 205 | 199 | 327 | 334 |
Gross Interest Expense |
204 | 205 | 199 | 327 | 334 |
Pretax Income |
-21,799 | -14,874 | -13,928 | -11,666 | -13,911 |
Income Tax |
0 | 0 | 0 | 0 | 0 |
Equity in Affiliates |
0 | 0 | 0 | 0 | 0 |
Consolidated Net Income |
-21,799 | -14,874 | -13,928 | -11,666 | -13,911 |
Minority Interest Expense |
0 | 0 | 0 | 0 | 0 |
Net Income |
-21,799 | -14,874 | -13,928 | -11,666 | -13,911 |
Extraordinaries & Discontinued Operations |
0 | 0 | 0 | 0 | 0 |
Extra Items & Gain/Loss Sale Of Assets |
0 | 0 | 0 | 0 | 0 |
Cumulative Effect - Accounting Chg |
0 | 0 | 0 | 0 | 0 |
Discontinued Operations |
0 | 0 | NA | 0 | 0 |
Net Income After Extraordinaries |
-21,799 | -14,874 | -13,928 | -11,666 | -13,911 |
Preferred Dividends |
0 | 0 | 0 | 0 | 0 |
Net Income available to Common |
-21,799 | -14,874 | -13,928 | -11,666 | -13,911 |
Operational EPS |
-0.86 | -0.59 | -0.61 | -0.52 | -0.68 |
EPS (basic) |
-0.86 | -0.59 | -0.63 | -0.55 | -0.72 |
EBITDA |
-21,544 | -14,631 | -13,157 | -9,714 | -12,752 |
Depreciation & Amortization Expense |
70 | 54 | 40 | 32 | NA |
Common Shares Outstanding |
25,347 | 25,360 | 22,186 | 21,246 | 19,408 |
Basic Shares Outstanding |
25,347 | 25,360 | 22,186 | 21,246 | 19,408 |
Diluted Shares Outstanding |
25,347 | 25,360 | 22,186 | 21,246 | 19,408 |
Diluted EPS after Extraordinary Items |
-0.86 | -0.59 | -0.63 | -0.55 | -0.72 |
Discont. Operations Per Share |
0 | 0 | 0 | 0 | 0 |
Continued operations EPS |
-0.86 | -0.59 | -0.63 | -0.55 | -0.72 |
*Figures in thousands of U.S. Dollars except shares outstanding.
